Table 2.

Nonalcoholic steatohepatitis with compensated cirrhosis—traditional clinical endpoints [11].

• Randomized, placebo-controlled, double-blind clinical trials.

• Stratification factors (e.g., T2DM, vitamin E, pioglitazone)

• Evaluation of drug effect “relative to placebo” on the “composite endpoint” of time from randomization to the first outcome event

• Spontaneous bacterial peritonitis

• Diuretic-resistant ascites(refractory ascites)

• Hepato-pleural effusion

• Variceal hemorrhage

• Hepatic encephalopathy

• Worsening of the MELD score to greater than or equal to 15

• Listing for liver transplant

• Liver transplantation

• Death from any cause